GlassScriptPhysician profile
David H Koota
NPI 1548367006
$895.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $102 · 2021: $169 · 2022: $177 · 2023: $54.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $200.91 | 2019-2022 | |
| Allergan, INC. | $183.27 | 2019-2022 | |
| Astellas Pharma US INC | $121.18 | 2020-2022 | |
| Ambu INC. | $110.80 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $94.09 | 2019-2021 | |
| Pfizer INC. | $55.80 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.12 | 2019 | |
| Boston Scientific Corporation | $16.86 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.11 | 2019 | |
| Merck Sharp & Dohme LLC | $14.69 | 2020 | |
| Abbvie INC. | $14.45 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.16 | 2019 | |
| Zyla Life Sciences, INC. | $11.78 | 2019 | |
| Medtronic USA, INC. | $11.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$1,399,984.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.